Frank Valone
Keine laufenden Positionen mehr
Profil
Dr. Frank H.
Valone, MD, is Chief Medical Officer at FibroGen, Inc.
Dr. Valone was previously employed as Senior Vice President-Medical Affairs by Bayhill Therapeutics, Inc., EVP-Clinical Development & Regulatory Affairs by Titan Pharmaceuticals, Inc., Clinical Associate Professor by Stanford University, Senior Vice President-Medical & Regulatory Affairs by Dendreon Corp., a Professor by Dartmouth-Hitchcock Medical Center, and an Associate Professor by The University of California, San Francisco.
He received his undergraduate degree from Hamilton College (New York) and a doctorate degree from Harvard University.
Ehemalige bekannte Positionen von Frank Valone
| Unternehmen | Position | Ende |
|---|---|---|
| FIBROGEN, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2016 |
Bayhill Therapeutics, Inc.
 Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
| TITAN PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
| DENDREON CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2002 |
| Stanford University | Corporate Officer/Principal | 01.01.2001 |
Ausbildung von Frank Valone
| Harvard University | Doctorate Degree |
| Hamilton College (New York) | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Bayhill Therapeutics, Inc.
Bayhill Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bayhill Therapeutics, Inc. develops and commercializes therapeutics. Its technology is BHT-DNA. The firm is a clinical-stage biopharmaceutical company leveraging its proprietary therapeutic BHT-DNA platform to develop a pipeline of novel and targeted treatment candidates for autoimmune diseases. Bayhill Therapeutics was founded by Lawrence Steinman, Hideki Garren, William H. Robinson and Paul J. Utz in 2001 and is headquartered in Palo Alto, CA. | Health Technology |
Dendreon Corp.
 Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
Dartmouth-Hitchcock Medical Center
 Dartmouth-Hitchcock Medical Center Hospital/Nursing ManagementHealth Services Dartmouth-Hitchcock Medical Center operates a general medical hospital. It is a nonprofit academic health system. The firm health care professionals offer clinical, education, research, nursing, specialty referrals and resource services. The company was founded in 1893 and is headquartered in Lebanon, NH. | Health Services |
